On November 5, 2025, the American Hospital Association highlighted new research tracking a major shift in state policy: more states are banning prior authorization requirements in private health plans for medications used to treat opioid use disorder (OUD). The Health Affairs study (published November 3, 2025) found that from 2015 to 2023, the number of states with these prohibitions grew from two to 22, reflecting rising urgency to remove administrative barriers that can delay time-sensitive treatment.
The analysis shows that the scope of these bans varies. Seven states enacted full prohibitions that bar prior authorization for all OUD medications, while 15 states adopted partial bans that still allow prior authorization under certain conditions. Over time, some states strengthened their laws: four states moved from partial to full bans, and many others broadened which medications or circumstances are covered.
The article also underscores why private insurance is a key focus. Researchers noted that people with private coverage are more likely to encounter prior authorization than those covered by Medicare or Medicaid, and more than one-third of people with OUD have private insurance. The policies examined center on access to evidence-based OUD medications such as methadone, buprenorphine, and naltrexone, where delays or denials can mean postponed care or unaffordable out-of-pocket costs.
At the same time, the study cautions that policy change is not the finish line. The researchers call for further evaluation of how these bans affect access to OUD medications, treatment outcomes, and patient preference, along with real-world insurer compliance and enforcement.
CLICK HERE to read the full article.